Latest News

IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.

SpaceX must prove its AI spending is worth the near-term pain.

Men's Social Security benefits exceed women's at every age, reflecting decades of workforce differences and shaping survivor protections.

Joby's technology impressed, but Wall Street is waiting for revenue.

AMD's net margin doubled while Qualcomm trades at a fraction of its rival's valuation, but customer concentration and competitive threats complicate both bets.

A couple of popular institutional trades are driving much of the purchasing activity.

If I had $10,000 to put into one consumer stock right now, this fast-growing coffee chain would be it, even with real risk attached.

NEAR Protocol is soaring in value this year, but how long can it keep up this performance?

SoundHound's story has changed. The next few quarters should reveal whether its expanded platform can convert greater customer reach into durable growth and stronger economics.

BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.

Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk commands a premium on exceptional profitability and GLP-1 dominance.

The LEO satellite developer still has plenty of upside potential.

ExxonMobil's pragmatic approach to Venezuela could reward investors, regardless of how much oil the company does or doesn't pump there.

Karellis increased his direct holdings by 26%, signaling confidence in the shipping company as its stock surges 61% over the past year.

Suddenly, it appears the Fed may hit pause on rate hikes in October.

Cathie Wood loves SpaceX, but her firm sold some of its shares this week.

The data center CPU market looks set to explode.

Brian Armstrong is sticking with his $400,000 Bitcoin target. His direction looks sound, but the 2030 deadline is a stretch.

Broadcom's 36% net margin and dominant AI accelerator position contrast sharply with Intel's foundry turnaround and negative free cash flow.

These consumer staples sell everyday brands that have funded decades of consistent dividends.

FTHF, HECO, and GTEK ETFs use niche strategies in emerging markets, hedged crypto, and smaller tech firms, each gaining 40% or more year to date in 2026.

Most investors are looking at something beyond the company's existing EV business.

Diversification is still one of the best strategies for long-term investing.

Vinicius Urias Favarao expanded his direct equity stake by 22%, signaling confidence in the Brazilian bank.